Back to Semaglutide research
semaglutide glp 1 agonist cohort n=35 2024-02-20 ClinicalTrials

Semaglutide and Exercise: A New Approach for Severe Obesity and Multimorbidity

Semaglutide and Physical Activity for Obesity and Multimorbidity

Background

Severe obesity, especially when coupled with multimorbidity (multiple chronic conditions), presents significant healthcare challenges. Many patients with morbid obesity (Class II and III) are deemed ineligible for bariatric surgery due to complex health issues or inability to independently achieve weight loss. This leaves a critical gap in effective, long-term treatment options for this vulnerable population. This study aims to explore the impact of an interdisciplinary Semaglutide-based treatment on cardiometabolic health, physical activity, and wellbeing in these specific patients.

Study Design

Population
35 individuals with severe obesity and multimorbidity who are ineligible for bariatric surgery.
Intervention
Semaglutide-based treatment over a two-year period.
Outcome
Changes in cardiometabolic health, physical activity, physical capacity, and wellbeing.

Results

This exploratory observational study is currently ACTIVE_NOT_RECRUITING and aims to describe changes in several key health parameters. Researchers will track anticipated improvements in cardiometabolic health (e.g., blood pressure, blood lipids, glucose control), physical activity levels, physical capacity, and overall wellbeing among the 35 estimated participants. The primary goal is to characterize these changes during the two-year interdisciplinary treatment period, providing insights into the comprehensive effects of the combined intervention. The study's central aim is to explore and describe changes in cardiometabolic health, physical activity, physical capacity, and wellbeing in patients undergoing Semaglutide-based weight loss treatment.

Why It Matters

This study is crucial because it addresses a highly underserved patient group: individuals with severe obesity and multimorbidity who cannot undergo bariatric surgery. The findings could establish a new, effective treatment paradigm for these complex patients, potentially improving their quality of life and reducing the burden of chronic diseases. If successful, this interdisciplinary approach could lead to new clinical guidelines and broader accessibility for Semaglutide-based therapies in this specific population. Future steps would likely involve larger, randomized controlled trials to confirm efficacy and generalize findings.


semaglutide glp 1 agonist glp-1r dose mentioned
Source: clinicaltrials:NCT06234111 · Ingested 2026-04-30 · Digest: gemini-2.5-flash